Medical investigations nowadays allow the incorporation of cure individuals in the analysis, especially for chronic diseases such as cancer. Therefore, survival models that incorporate the cured patients in the analysis are called cure rate models. In this paper, we propose an analytical approach for parametric estimation of the cure fraction in cancer clinical trials based on the bounded cumulative hazard (BCH) model with covariates involved in the data set. The analysis is constructed by means of the exponential distribution in the case of left censoring and within the framework of the expectation maximization (EM) algorithm. The analysis provided the analytical solution and a simulation study for the cure rate parameter
Copyright © 2013 Shunzo Maetani, John W. Gamel. This is an open access article distributed under the...
Censored data are considered to be of the interval type where the upper and lower bounds of an event...
Due to significant progress in cancer treatments and management in survival studies involving time t...
In population based cancer clinical trials, a proportion of patients will never experience the inter...
In this article, we consider the Bounded Cumulative Hazard (BCH) model that is more appropriate than...
A significant proportion of patients in cancer clinical trials can be cured. That is, the symptoms o...
In cancer clinical trials, a significant fraction of patients can be cured, that is, the symptoms of...
In cancer studies many patients will never experience the event of concern and are hence considered ...
Cure rate models are survival models consisting of a cured fraction and an uncured fraction. These m...
In most recent clinical studies, the focus is on estimation of the proportion of patients who are cu...
The authors propose a novel class of cure rate models for right-censored failure time data. The clas...
This study deals with the analysis of the cure rate estimation based on the Bounded Cumulative Hazar...
In population-based cancer studies, cure is said to occur when the mortality (hazard) rate in the di...
We develop a multivariate cure survival model to estimate lifetime patterns of colorectal cancer scr...
In most recent clinical studies, the focus is on estimation of the proportion of patients who are cu...
Copyright © 2013 Shunzo Maetani, John W. Gamel. This is an open access article distributed under the...
Censored data are considered to be of the interval type where the upper and lower bounds of an event...
Due to significant progress in cancer treatments and management in survival studies involving time t...
In population based cancer clinical trials, a proportion of patients will never experience the inter...
In this article, we consider the Bounded Cumulative Hazard (BCH) model that is more appropriate than...
A significant proportion of patients in cancer clinical trials can be cured. That is, the symptoms o...
In cancer clinical trials, a significant fraction of patients can be cured, that is, the symptoms of...
In cancer studies many patients will never experience the event of concern and are hence considered ...
Cure rate models are survival models consisting of a cured fraction and an uncured fraction. These m...
In most recent clinical studies, the focus is on estimation of the proportion of patients who are cu...
The authors propose a novel class of cure rate models for right-censored failure time data. The clas...
This study deals with the analysis of the cure rate estimation based on the Bounded Cumulative Hazar...
In population-based cancer studies, cure is said to occur when the mortality (hazard) rate in the di...
We develop a multivariate cure survival model to estimate lifetime patterns of colorectal cancer scr...
In most recent clinical studies, the focus is on estimation of the proportion of patients who are cu...
Copyright © 2013 Shunzo Maetani, John W. Gamel. This is an open access article distributed under the...
Censored data are considered to be of the interval type where the upper and lower bounds of an event...
Due to significant progress in cancer treatments and management in survival studies involving time t...